|
|
FOCUS: Chemical giant diversifies biotech portfolio - Indianapolis Business Journal
Indianapolis Business JournalFOCUS: Chemical giant diversifies biotech portfolioIndianapolis Business Journal, IN - 4 hours agoBy 2015, Peribere hopes to oversee a balanced portfolio of agricultural chemical and biotech products. ?We?re in the stone age of biotechnology,? he said. …
Bodisen Biotech H1 net income down 87.1 pct as sales fall 70 pct UPDATE (Sharewatch)
(Updates reasons for fall in net income) LONDON (Thomson Financial) - China-based fertilizer firm Bodisen Biotech Inc reported an 87.1 pct fall in its first-half net income after a 70 pct decline in its sales.
Monsanto predicts global biotech seed sales could triple
TheStar.com.my Sep 27 2007 4:43AM GMT…
Hey, Merck, All the Other Pharmas and Biotechs Want to Thank You
Genome Technology Sep 26 2007 4:30AM GMT…
Saamya Biotech IPO opens for subscription - Moneycontrol.com
Saamya Biotech IPO opens for subscriptionMoneycontrol.com, India - 42 minutes agoSaamya Biotech is open for subscription with an initial public offering (IPO) of 15 lakh shares of Rs 10 each to raise around Rs 15 crore. …
Biotech lures science graduates more than agritech: ASSOCHAM - India Infoline.com
Biotech lures science graduates more than agritech: ASSOCHAMIndia Infoline.com, India - 1 hour agoOn the contrary, advance understanding of the biotech sector would land majority of young scientists for better placement and there is no point, …
Legal tussles send biotech to bankruptcy
Business Journal of Milwaukee:
ABL Biotech to produce DHA
Therapeutics Daily Sep 22 2007 1:40AM GMT…
Singapore biotech drive loses star UK scientists - Reuters UK
Singapore biotech drive loses star UK scientistsReuters UK, UK - 13 minutes agoSINGAPORE (Reuters) - Top scientists David and Birgitte Lane are set to leave Singapore to take up new positions at Scotland’s University of Dundee, …
Biotech deal costs soar - Reuters
Biotech deal costs soarReuters - 1 hour agoLONDON, Sept 20 (Reuters) - The price of acquiring promising medicines from biotech firms is soaring, reflecting big drugmakers’ growing hunger for assets …